New Zealand is a key research location for studies in skin cancer, multiple sclerosis, asthma and several other conditions. PRA International can now monitor New Zealand study sites with in-country staff. The local presence, combined with PRA’s continued expansion in the region, is expected to further enhance its position as a CRO.
PRA’s New Zealand staff is expected to work closely with employees in the PRA Sydney, Australia office. This presents an ideal situation for collaboration, since the countries share similar health care and clinical research environments. In addition, companies frequently conduct clinical trials simultaneously across Australia and New Zealand, and their health specialists are linked through joint professional associations and research organisations.
Edward Ian, senior director of operations for Asia-Pacific at PRA, said: “We are very pleased with the expansion to New Zealand. It continues our expansion in this critical region and is an ideal complement to our operations in Australia.”